Searchable abstracts of presentations at key conferences in endocrinology

ea0044p50 | Bone and Calcium | SFEBES2016

Impact of hepatitis B-related chronic liver disease and its therapy on bone health

Paul Thomas V , Kapoor Nitin , Gangadharan Sajith Kattiparambil , Shetty Sahana , Goel Ashish , Zachariah Uday , Eapen Chundamannil E

Objective: To study the impact of HBV related chronic liver disease (CLD) and its treatment with Tenofovir on bone health in Indian subjects.Methods: This cross-sectional study included men between 18 and 60 years and comprised of three groups: Group 1 was treatment naïve HBV-related CLD (n=79), Group 2 – those with HBV-related CLD on tenofovir for at least 1 year duration (n=136), Group 3 – normal age, sex and BMI-matche...

ea0072p4 | (1) | UKINETS2020

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

Khanna Amardeep , Cianci Nicole , Abbas Shah Husnain , Goel Ashish , Jebril Asma , Chauhan Jessica , Pipe Michelle , Shetty Shishir , Weston Christopher , Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Shah Tahir

Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze and can be challenging to manage. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase 3 clinical trials but la...